Contributions of Intestine and Plasma to the Presystemic Bioconversion of Vicagrel, an Acetate of Clopidogrel

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2013 Sep 17

PMID 24037619

Citations 10

Authors

Zhixia Qiu

Ning Li

Ling Song

Yang Lu

Jing Jing

Harendra S Parekha

Wenchao Gao

Fengjie Tian

Xin Wang

Shuangxia Ren

Xijing Chen

Affiliations

Soon will be listed here.

Abstract

Purpose: To investigate the contributions of intestine and plasma to the presystemic bioconversion of vicagrel, and track its subsequent bioconversion to 2-oxo-clopidogrel in vivo and in vitro to rationalize the design of vicagrel, an acetate analogue of clopidogrel.

Methods: The concentration-time profiles of 2-oxo-clopidogrel and active metabolite (AM) in presystem and circulation system was determined in the cannulated rats. Also, the rat intestinal S9 and human intestinal microsomes were conducted to examine the formation of 2-oxo-clopidogrel and AM. Meanwhile, the esterases in plasma and intestinal fractions responsible for the bioconversion of vicagrel to 2-oxo-clopidogrel were screened by the esterase inhibition and recombinant esterases.

Results: The intestine was responsible for the formation of 2-oxo-clopidogrel and AM in vivo and in vitro, where carboxylesterases 2 (CE2) contributed greatly to the vicagrel cleavage during absorption. Other related esterases in plasma were paraoxonases (PON), carboxylesterases 1 (CE1) and butyrylcholine esterases (BChE).

Conclusion: The findings rationalized the prodrug design hypothesis that vicagrel could overcome the extensive invalid hydrolysis of clopidogrel by the hepatic CE1 but experience the extensive hydrolysis to 2-oxo-clopidogrel and subsequent oxidation to AM in the intestine. This also supported the theory of improved pharmacological activity through facilitated formation of 2-oxo-clopidogrel, thus warranting much needed future clinical pharmacokinetic studies of vicagrel.

Citing Articles

Hydrolytic Metabolism of Withangulatin A Mediated by Serum Albumin Instead of Common Esterases in Plasma.

Zhuang Y, Wang Y, Li N, Meng H, Li Z, Luo J Eur J Drug Metab Pharmacokinet. 2023; 48(4):363-376.

PMID: 37344636 DOI: 10.1007/s13318-023-00834-8.

Fluorine impairs carboxylesterase 1-mediated hydrolysis of T-2 toxin and increases its chondrocyte toxicity.

Jia Y, Shi S, Cheng B, Cheng S, Liu L, Meng P Front Nutr. 2022; 9:935112.

PMID: 35990316 PMC: 9381868. DOI: 10.3389/fnut.2022.935112.

Predicting the Effects of CYP2C19 and Carboxylesterases on Vicagrel, a Novel P2Y12 Antagonist, by Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Approach.

Liu S, Wang Z, Tian X, Cai W Front Pharmacol. 2021; 11:591854.

PMID: 33424602 PMC: 7793822. DOI: 10.3389/fphar.2020.591854.

Impacts of CYP2C19 genetic polymorphisms on bioavailability and effect on platelet adhesion of vicagrel, a novel thienopyridine P2Y inhibitor.

Zhang Y, Zhu X, Zhan Y, Li X, Liu C, Zhu Y Br J Clin Pharmacol. 2020; 86(9):1860-1874.

PMID: 32267573 PMC: 7444798. DOI: 10.1111/bcp.14296.

Platelet inhibitory activity, tolerability, and safety of vicagrel, a novel thienopyridine P2Y12 inhibitor.

Li H, Chen H, Chen W, Xu H, Yuan F, Yang M Medicine (Baltimore). 2020; 99(4):e18683.

PMID: 31977858 PMC: 7004678. DOI: 10.1097/MD.0000000000018683.

References

Yusuf S, Zhao F, Mehta S, Chrolavicius S, Tognoni G, Fox K . Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345(7):494-502. DOI: 10.1056/NEJMoa010746. View

Farid N, Kurihara A, Wrighton S . Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol. 2009; 50(2):126-42. DOI: 10.1177/0091270009343005. View

Hagihara K, Kazui M, Ikenaga H, Nanba T, Fusegawa K, Takahashi M . Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs. Xenobiotica. 2009; 39(3):218-26. DOI: 10.1080/00498250802650077. View

Hosokawa M . Structure and catalytic properties of carboxylesterase isozymes involved in metabolic activation of prodrugs. Molecules. 2008; 13(2):412-31. PMC: 6245361. DOI: 10.3390/molecules13020412. View

Williams E, Jones K, Ponsler G, Lowery S, Perkins E, Wrighton S . The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2. Drug Metab Dispos. 2008; 36(7):1227-32. DOI: 10.1124/dmd.107.020248. View

Kuo C, La Du B . Calcium binding by human and rabbit serum paraoxonases. Structural stability and enzymatic activity. Drug Metab Dispos. 1998; 26(7):653-60. View

Yamaori S, Fujiyama N, Kushihara M, Funahashi T, Kimura T, Yamamoto I . Involvement of human blood arylesterases and liver microsomal carboxylesterases in nafamostat hydrolysis. Drug Metab Pharmacokinet. 2006; 21(2):147-55. DOI: 10.2133/dmpk.21.147. View

Imai T, Ohura K . The role of intestinal carboxylesterase in the oral absorption of prodrugs. Curr Drug Metab. 2010; 11(9):793-805. DOI: 10.2174/138920010794328904. View

Ancrenaz V, Desmeules J, James R, Fontana P, Reny J, Dayer P . The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitro. Br J Pharmacol. 2012; 166(8):2362-70. PMC: 3448899. DOI: 10.1111/j.1476-5381.2012.01946.x. View

10.

Dansette P, Rosi J, Bertho G, Mansuy D . Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer. Chem Res Toxicol. 2011; 25(2):348-56. DOI: 10.1021/tx2004085. View

11.

Bahar F, Ohura K, Ogihara T, Imai T . Species difference of esterase expression and hydrolase activity in plasma. J Pharm Sci. 2012; 101(10):3979-88. DOI: 10.1002/jps.23258. View

12.

Tang M, Mukundan M, Yang J, Charpentier N, LeCluyse E, Black C . Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol Exp Ther. 2006; 319(3):1467-76. DOI: 10.1124/jpet.106.110577. View

13.

Berry L, Wollenberg L, Zhao Z . Esterase activities in the blood, liver and intestine of several preclinical species and humans. Drug Metab Lett. 2009; 3(2):70-7. DOI: 10.2174/187231209788654081. View

14.

Dean R, CHRISTIAN C, Sample R, Bosron W . Human liver cocaine esterases: ethanol-mediated formation of ethylcocaine. FASEB J. 1991; 5(12):2735-9. DOI: 10.1096/fasebj.5.12.1916095. View

15.

Walenga R, Vanderhoek J, Feinstein M . Serine esterase inhibitors block stimulus-induced mobilization of arachidonic acid and phosphatidylinositide-specific phospholipase C activity in platelets. J Biol Chem. 1980; 255(13):6024-7. View

16.

Liederer B, Borchardt R . Enzymes involved in the bioconversion of ester-based prodrugs. J Pharm Sci. 2006; 95(6):1177-95. DOI: 10.1002/jps.20542. View

17.

Wei R, Chu F . Modification of in vitro metabolism of T-2 toxin by esterase inhibitors. Appl Environ Microbiol. 1985; 50(1):115-9. PMC: 238581. DOI: 10.1128/aem.50.1.115-119.1985. View

18.

Liston D, Nielsen J, Villalobos A, Chapin D, Jones S, Hubbard S . Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease. Eur J Pharmacol. 2004; 486(1):9-17. DOI: 10.1016/j.ejphar.2003.11.080. View

19.

Hochholzer W, Wiviott S, Antman E, Contant C, Guo J, Giugliano R . Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38.... Circulation. 2011; 123(23):2681-9. DOI: 10.1161/CIRCULATIONAHA.110.002683. View

20.

Gurbel P, Bliden K, Hiatt B, OConnor C . Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003; 107(23):2908-13. DOI: 10.1161/01.CIR.0000072771.11429.83. View